African healthcare financing gap widens as $1 billion fund sits dormant

Afreximbank’s $1 billion healthcare manufacturing allocation sits almost entirely untouched, with just $75,000 deployed over two years. That figure, cited by Brian Deaver, CEO of the African Medical Centre of Excellence, captures the financing gap his Abuja-based facility is trying to close, one insurance contract and employer agreement at a time.

Deaver made the case at the Africa Social Impact Summit on Wednesday, framing Africa’s outbound medical tourism not as a clinical failure but as a structural financing problem. Patients across the continent lack adequate insurance coverage to access specialist care locally, so capital flows abroad instead. “We have to figure out how individuals finance their health care as well, and that’s where insurance comes in,” he said.

AMCE, which received its full operating license in November after opening just over a year ago, has moved quickly to address that gap. The facility is now contracting with health maintenance organizations and insurance companies across Nigeria, the broader continent and internationally, aiming to ensure that patients with existing coverage can use their policies for specialist services including cancer care, hematology and cardiovascular treatment.

Meanwhile, the center is building direct-access channels that bypass the insurance system entirely. Deaver announced a deal with a representative body for Nigerian teachers to offer discounted rates for uninsured or underinsured educators, covering screenings, checkups and treatment for more serious conditions. He said the arrangement would be formally signed.

The financial architecture behind AMCE’s subsidized care and research programs runs through the Africa Life Sciences Foundation, which has raised $75 million, largely from Afreximbank. Deaver was careful to separate that figure from AMCE’s own roughly $250 million phase-one construction budget. The foundation operates across three areas: subsidizing care for patients who cannot afford treatment, funding clinical trials tailored to African populations, and supporting healthcare capital projects at AMCE or elsewhere.

The research mandate carries its own economic logic. Deaver argued that most medications in global use were developed using American and European genomic data, creating a mismatch between available treatments and African patient populations. Localized drug development and adaptation, he contends, would improve efficacy and reduce the long-term cost burden of suboptimal therapies.

That $1 billion Afreximbank allocation, by contrast, points to a different kind of opportunity cost. The funds are earmarked for healthcare manufacturing companies willing to establish operations in Nigeria, yet the near-total absence of drawdowns suggests that either awareness is low, conditions are unattractive, or both. Deaver framed the gap as a missed chance to build local production capacity for medical supplies, implants and equipment, reducing import dependence and moving toward a more self-sustaining healthcare economy.

For AMCE, the immediate task is converting summit conversations into signed agreements. Deaver acknowledged that many Nigerians remain unaware that advanced specialist services now exist locally in Abuja (the facility is partnered with King’s College Hospital London). Building that awareness is as much a commercial challenge as a public health one: without patient volume, the insurance partnerships lose their value proposition for insurers, and the broader model stalls.

The open question is whether AMCE can operationalize its insurance contracts fast enough to demonstrate that retaining healthcare spending on the continent is genuinely viable, before the next round of outbound medical tourism spending makes the case against it.